Research programme: alpha-synuclein inhibitors - Prothena Corporation/Roche

Drug Profile

Research programme: alpha-synuclein inhibitors - Prothena Corporation/Roche

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Neotope Biosciences
  • Developer Prothena; Roche
  • Class Monoclonal antibodies
  • Mechanism of Action Alpha-synuclein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Parkinson's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in Ireland (Parenteral)
  • 11 Dec 2013 Alpha-synuclein inhibitors licensed to Roche worldwide
  • 03 Aug 2011 Preclinical trials in Parkinson's disease in Ireland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top